International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclona...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology Jg. 17; H. 8; S. e328 - e346
Hauptverfasser: Kumar, Shaji, Paiva, Bruno, Anderson, Kenneth C, Durie, Brian, Landgren, Ola, Moreau, Philippe, Munshi, Nikhil, Lonial, Sagar, Bladé, Joan, Mateos, Maria-Victoria, Dimopoulos, Meletios, Kastritis, Efstathios, Boccadoro, Mario, Orlowski, Robert, Goldschmidt, Hartmut, Spencer, Andrew, Hou, Jian, Chng, Wee Joo, Usmani, Saad Z, Zamagni, Elena, Shimizu, Kazuyuki, Jagannath, Sundar, Johnsen, Hans E, Terpos, Evangelos, Reiman, Anthony, Kyle, Robert A, Sonneveld, Pieter, Richardson, Paul G, McCarthy, Philip, Ludwig, Heinz, Chen, Wenming, Cavo, Michele, Harousseau, Jean-Luc, Lentzsch, Suzanne, Hillengass, Jens, Palumbo, Antonio, Orfao, Alberto, Rajkumar, S Vincent, Miguel, Jesus San, Avet-Loiseau, Herve
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Elsevier Ltd 01.08.2016
Elsevier Limited
Schlagworte:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biopsy
Bone marrow
Consensus
Flow cytometry
Hematology, Oncology and Palliative Medicine
Humans
Immunoglobulins
Methods
Multiple myeloma
Multiple Myeloma - drug therapy
Neoplasm, Residual - chemically induced
Neoplasm, Residual - diagnosis
Practice Guidelines as Topic - standards
Proteins
Transplants & implants
Urine
Working groups
ISSN:1470-2045, 1474-5488, 1474-5488
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1470-2045
1474-5488
1474-5488
DOI:10.1016/S1470-2045(16)30206-6